GUÍA MANEJO ANTIRRETROVIRAL PERSONAS VIH

therapy-naïve HIV-infected individuals from 40 United States
cities. HIV Clin Trial. 2007;8:1-8.
113. Williamd A.B, Amico K.R, Bova C, Womack J.A. A proposal for
quality standards for measuring medication adherence in research.
AIDS Behav. 2013;17(1): 284-97.
114. Honghu L., Wilson I.B, Goggin K, Bangsberg D.R et al. MACH14:
A multi-site collaboration on ART adherence aming 14
institutions. AIDS Behav. 2013;17(1):127-141
115. Reynolds N.R. Adherence to antiretroviral therapies: state of the
science. Curr HIV Res. 2004;2(3):207-14
116. Pearson C.R., Simoni J.M., Hoff P, Kurth A.E, Martin D.P.
Assessing antiretroviral adherence via electronic drug monitoring
and self-report: an examination of key methodological issues.
AIDS Behav. 2007;11(2):161-73
117. Reynolds NR, Sun J, Nagaraja HN, Gifford AL, Wu AW, Chesney
MA. Optimizing measurements of self-reported adherence with
the ACTG adherence questionary: A cross protocol analysis.J
AcquirImmuneDeficSyndr. 2007; 46: 402-409.
118. Stone VE, Jordan J, Tolson J, et. al. Perspectives on adherence and
simplicity for HIV-infected patients on antiretroviral therapy:
self-report of the relative importance of multiple attributes of
highly active antiretroviral therapy (HAART) regimens in
predicting adherence. J Acquir Immune Defic Syndr. 2004 Jul
1;36(3):808-16.
Capítulo 3
1. Pérez LF, Morán MA, Santos JI.Síndrome de Inmunodeficiencia
adquirida (SIDA) en pediatría. Informe del primer caso en
México. Bol Med Hosp Infant Mex 1986;43:729.
2. De Martino M, Tovo PA, Balducci M, et al. Reduction in mortality
with availability of antiretroviral therapy for children with
perinatal HIV-1 infection. Italian Register for HIV Infection in
Children and the Italian National AIDS Registry. JAMA.2000;
284(2):190-7.
http://www.ncbi.nlm.nih.gov/pubmed/10889592
3. Gibb DM, Duong T, Tookey PA, et al. National Study of HIV in
Pregnancy and Childhood Collaborative HIV Paediatric Study.
Decline in mortality, AIDS, and hospital admissions in perinatally
HIV-1 infected children in the United Kingdom and Ireland.
BMJ.2003; 327(7422):1019.
http://www.ncbi.nlm.nih.gov/pubmed/14593035
4. Gortmaker S, Hughes M, Cervia J, et al. Effect of combination
therapy including protease inhibitors on mortality among children
and adolescents infected with HIV-1. N Engl J Med.2001;
345(21):1522-8.
http://www.ncbi.nlm.nih.gov/pubmed/11794218
5. Viani RM, Araneta MR, Deville JG, Spector SA. Decrease in
hospitalization and mortality rates among children with
perinatally acquired HIV type 1 infection receiving highly active
antiretroviral therapy. Clin Infect Dis.2004 ; 39(5):725-31.
http://www.ncbi.nlm.nih.gov/pubmed/15356789
6. Centers for Disease Control and Prevention. 1994 revised
classification system for human immunodeficiency virus infection
in children less than 13 years of age. MMWR.1994. 43(RR-12):1-
10. http://www.cdc.gov/hiv/pubs/mmwr/mmwr1994.htm
7. Nachman SA, Lindsey JC, Moye J, et al. Growth of human
immunodeficiency virus-infected children receiving highly active
antiretroviral therapy. Pediatr Infect Dis J.2005; 24(4):352-7.
http://www.ncbi.nlm.nih.gov/pubmed/15818296
8. Storm DS, Boland MG, Gortmaker SL, et al. Protease inhibitor
combination therapy, severity of illness, and quality of life among
children with perinatally acquired HIV-1 infection.
Pediatrics.2005;
115(2):e173-82.
http://www.ncbi.nlm.nih.gov/pubmed/156299
9. Paediatric European Network for Treatment of AIDS (PENTA).
Five year follow up of vertically HIV infected children in a
randomised double blind controlled trial of immediate versus
deferred zidovudine: the PENTA 1 trial. Arch Dis Child. 2001;
84(3):230-6. http://www.ncbi.nlm.nih.gov/pubmed/11207172
10. Selik RM, Lindegren ML. Changes in deaths reported with human
immunodeficiency virus infection among United States children
less than thirteen years old, 1987 through 1999. Pediatr Infect Dis
J.2003; 22(7):635-41.
http://www.ncbi.nlm.nih.gov/pubmed/12867840
11. McConnell MS, Byers RH, Frederick T, et al. Trends in
antiretroviral therapy use and survival rates for a large cohort of
HIV-infected children and adolescents in the United States, 1989-
2001. J Acquir Immune Defic Syndr.2005 ; 38(4):488-94.
http://www.ncbi.nlm.nih.gov/pubmed/15764966
12. Shanbhag MC, Rutstein RM, Zaoutis T, et al. Neurocognitive
functioning in pediatric human immunodeficiency virus infection:
effects of combined therapy. Arch Pediatr Adolesc Med.2005;
159(7):651-6.
http://www.ncbi.nlm.nih.gov/pubmed/15996999
13. Chiriboga CA, Fleishman S, Champion S, et al. Incidence and
prevalence of HIV encephalopathy in children with HIV infection
receiving highly active anti-retroviral therapy (HAART). J
Pediatr.2005; 146(3):402-7.
http://www.ncbi.nlm.nih.gov/pubmed/15756229
14. Villalobos AP, Plascencia GE, Romano ML, Pavia RN. Patrón de
la enfermedad y sobrevida en niños y adolescentes infectados por
VIH manejados con terapia antirretroviral altamente activa. Bol
Med Hosp Infant Mex. 2009; 66(4): 314-324.
15. Diniz LO, Pinto JA. Calidad de vida de niños infectados con VIH
en Brasil. Bol Med Hosp Infant Mex. 2009; 66(4): 325-334.
16. HIV Paediatric Prognostic Markers Collaborative Study.
Predictive value of absolute CD4 cell count for disease progression
in untreated HIV-1-infected children. AIDS.2006; 20(9):1289-
94. http://www.ncbi.nlm.nih.gov/pubmed/16816558
17. HIV Paediatric Prognostic Markers Collaborative Study Group.
Short-term risk of disease progression in HIV-1-infected children
receiving no antiretroviral therapy or zidovudine monotherapy:
estimates according to CD4 percent, viral load, and age.
Lancet.2003; 362(9396):1605-11.
http://www.ncbi.nlm.nih.gov/pubmed/14630440
18. Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA,
Jean-Philippe P, McIntyre JA; CHER Study Tea. Early
antiretroviral therapy and mortality among HIV-infected infants.
AIDS Care. 2009; Mar,21(3):329-34.
19. Galli L, de Martino M, Tovo PA, Gabiano C, Zappa M. Predictive
value of the HIV paediatric classification system for the long-term
course of perinatally infected children. Int JEpidemiol. 2000
Jun;29(3):573-8.
20. Dunn D, Woodburn P, Duong T, Peto J, Phillips A, Gibb DM, et
al. Current CD4 cell count and the short-term risk of AIDS and
death before the availability of effective antiretroviral therapy in
HIVinfected children and adults. J Infect Dis. 2008 Feb
1;197(3):398-404.
21. HIV Paediatric Prognostic Markers Collaborative Study Group.
Use of total lymphocyte count for informing when to start
antiretroviral therapy in HIV-infected children: a meta-analysis
of longitudinal data. Lancet. 2005 Nov 26;366(9500):1868-74.
22. HIV Paediatric Prognostic Markers Collaborative Study and the
CASCADE Collaboration, Dunn D, Woodburn P, et al. Current
CD4 cell count and the short-term risk of AIDS and death before
the availability of effective antiretroviral therapy in HIV-infected
children and adults. J Infect Dis.2008 ; 197(3):398-404.
http://www.ncbi.nlm.nih.gov/pubmed/18248303
23. Mofenson LM, Korelitz J, Meyer WA, et al. The relationship
between serum human immunodeficiency virus type 1 (HIV-1)
RNA level, CD4 lymphocyte percent, and long-term mortality
risk in HIV-1-infected children. National Institute of Child
Health and Human Development Intravenous Immunoglobulin
Clinical Trial Study Group. J Infect Dis.1997; 175(5):1029-38.
http://www.ncbi.nlm.nih.gov/pubmed/9129063
24. Palumbo PE, Raskino C, Fiscus S, et al. Predictive value of
quantitative plasma HIV RNA and CD4+ lymphocyte count in
HIV-infected infants and children. JAMA.1998; 279(10):756-
61.
25. Abrams EJ, Wiener J, Carter R, et al. Maternal health factors and
early pediatric antirretroviral therapy influence the rate of
perinatal HIV-1 disease progression in children. AIDS.
2003;17:867-877.
26. Faye A, Le Chenadec J, Dollfus C, et al. Early versus deferred
antirretroviral multidrug therapy in infants infected with HIV
type 1. CID. 2004;38:1692-1698.
27. Goetghebuer, Tessa a; Haelterman, Edwige a; Le Chenadec,
Jerome b; Dollfus, Catherine c; Gibb, Diana d; Judd, Ali d; Green,
Hannah d; Galli, Luisa e; Ramos, Jose Tomas f; Giaquinto, Carlo
g; Warszawski, Josiane bhi; Levy, Jack a; for the European Infant
Collaboration group. Effect of early antiretroviral therapy on the
risk of AIDS/death in HIV-infected infants. AIDS.
2009.23(5):597-604.
28. Chiappini E, Galli L, Gabiano C, et al. Early triple therapy vs mono
or dual therapy for children with perinatal HIV infection. JAMA.
2006;295:628-631.
29. Chiappini E, Galli L, Tovo PA, et al. Virologic, immunologic, and
clinical benefits from early combined antirretroviral therapy in
infants with perinatal HIV-1 infection. AIDS. 2006;20:207-215.
30. Newell ML, Patel D, Goetghebuer T, Thorne C. European
Collaborative Study. CD4 cell response to antiretroviral therapy
in children with vertically acquired HIV infection: is it associated
with age at initiation? J Infect Dis. 2006;193:954-962.
175